Quality and purity vary widely among suppliers, introducing risk
The Addiction study does not prove that GLP-1 medications directly lower the risks of opioid overdose and alcohol intoxication, only that people taking them seemed to be helped
Since tirzepatide typically produces greater weight loss (20-25% body weight versus 15-17% with semaglutide at weight loss doses), more tirzepatide users may experience telogen effluvium simply because they lost more weight faster
This perspective is consistent with a recent joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, which identified nutritional and lifestyle priorities as essential components of effective and durable GLP-1based obesity care [146]
In the STEP-1 trial, semaglutide 2.4 mg produced a total lean mass loss of 6.92 kg, which represented 13.2% of baseline lean mass